PFIZER INC Increase (Decrease) in Accounts Payable and Accrued Liabilities
PFIZER INC (PFE) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $1.15 billion for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2012-02-28
- PFIZER INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2011 was $1.15B, a 39.20% increase from fiscal 2010.
- PFIZER INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2010 was $824.00M, a 45.10% decline from fiscal 2009.
- PFIZER INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2009 was $1.50B, a 65.17% decline from fiscal 2008.
- PFIZER INC increase (decrease) in accounts payable and accrued liabilities for fiscal 2008 was $4.31B, a 185.62% increase from fiscal 2007.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|
| 2011-12-31 | $1.15B 10-K · filed 2012-02-28 | |
| 2010-12-31 | $824.00M 10-K · filed 2012-02-28 | $827.00M 10-K · filed 2011-02-28 |
| 2009-12-31 | $1.50B 10-K · filed 2012-02-28 | $1.70B 10-K · filed 2010-02-26 |
| 2008-12-31 | $4.31B 10-K · filed 2011-02-28 | $3.80B 10-K · filed 2010-02-26 |
| 2007-12-31 | $1.51B 10-K · filed 2010-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |